USPSTF’s Wanda Nicholson: Final recommendation to start breast cancer screening at 40 will save 20% more lives

As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines

The U.S. Preventive Services Task Force is at risk of losing the expertise, evidence-review infrastructure, and institutional culture that has made it a model for evidence-based medicine. In July 2025, David Ransohoff, a gastroenterologist and clinical epidemiologist in the Division of Gastroenterology and Hepatology at University of North Carolina School of Medicine, noted that HHS...

October 16, 2026

Vol.52 No.38

By Claire Marie Porter and Paul Goldberg

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

A Fox Chase Cancer Center team is combining a rare longitudinal family cohort, whole-genome sequencing, AI-guided analysis, and laboratory validation to investigate why people with similar inherited susceptibility can experience very different cancer outcomes.

October 16, 2026

Vol.52 No.38

By Fox Chase Cancer Center

Clinical Roundup

ACS studies find widening rural-urban survival and mortality gaps for women with breast cancer

Life-saving advances in breast cancer care are failing to reach rural America equally. In two large studies led by the American Cancer Society, scientists found that survival and mortality disparities between rural and urban women diagnosed with breast cancer widened over time in the United States.

October 16, 2026

Vol.52 No.38

Perspective

Oncology has a semantics problem: How do we define “early stage”?

I recently found myself asking a question that I thought had an obvious answer: What is early-stage cancer?

FDA approves tucatinib + trastuzumab + pertuzumab for maintenance treatment of HER2+ breast cancer

FDA approved Tuksya (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive breast cancer following induction treatment. The approval expands the use of Tuksya to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance treatment option that may help further delay disease progression.

October 09, 2026

Vol.52 No.37

Regulatory News

Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?

Nearly two years after FDA issued a final rule requiring radiologists to tell women whether their breasts are “dense” or “not dense” after a mammogram, the notification has become nearly universal.

October 02, 2026

Vol.52 No.36

By Claire Marie Porter

USPSTF’s Wanda Nicholson: Final recommendation to start breast cancer screening at 40 will save 20% more lives

YOU MAY BE INTERESTED IN

As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

ACS studies find widening rural-urban survival and mortality gaps for women with breast cancer

Oncology has a semantics problem: How do we define “early stage”?

FDA approves tucatinib + trastuzumab + pertuzumab for maintenance treatment of HER2+ breast cancer

Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?

Renew today!

Subscriber content

Never miss an issue!

Login

USPSTF’s Wanda Nicholson: Final recommendation to start breast cancer screening at 40 will save 20% more lives

YOU MAY BE INTERESTED IN

As trust in USPSTF erodes, cancer screening is in perilDavid Ransohoff predicts a “Wild West” era without evidence-based screening guidelines

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

ACS studies find widening rural-urban survival and mortality gaps for women with breast cancer

Oncology has a semantics problem: How do we define “early stage”?

FDA approves tucatinib + trastuzumab + pertuzumab for maintenance treatment of HER2+ breast cancer

Two years after FDA’s breast density notification rule, there is still no standard for follow-upSo far, 38 million patients have received a dense breast notification. Now what?

Never miss an issue!

Login

As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines

Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?